Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
Abstract: Parkinson's disease predisposing LRRK2 kinase phosphorylates a group of Rab GTPase proteins including Rab29, within the effector‐binding switch II motif. Previous work indicated that Rab29, located within the PARK16 locus mutated in Parkinson's patients, operates in a common pathway with LRRK2. Here, we show that Rab29 recruits LRRK2 to the trans‐Golgi network and greatly stimulates its kinase activity. Pathogenic LRRK2 R1441G/C and Y1699C mutants that promote GTP binding are more readily recruited to the Golgi and activated by Rab29 than wild‐type LRRK2. We identify conserved residues within the LRRK2 ankyrin domain that are required for Rab29‐mediated Golgi recruitment and kinase activation. Consistent with these findings, knockout of Rab29 in A549 cells reduces endogenous LRRK2‐mediated phosphorylation of Rab10. We show that mutations that prevent LRRK2 from interacting with either Rab29 or GTP strikingly inhibit phosphorylation of a cluster of highly studied biomarker phosphorylation sites (Ser910, Ser935, Ser955 and Ser973). Our data reveal that Rab29 is a master regulator of LRRK2, controlling its activation, localization, and potentially biomarker phosphorylation.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase ; volume:37 ; number:1 ; year:2018 ; pages:1-18 ; extent:18
The EMBO journal / European Molecular Biology Organization ; 37, Heft 1 (2018), 1-18 (gesamt 18)
- Urheber
-
Purlyte, Elena
Dhekne, Herschel S.
Sarhan, Adil R.
Gomez, Rachel
Lis, Pawel
Wightman, Melanie
Martinez, Terina N.
Tonelli, Francesca
Pfeffer, Suzanne R.
Alessi, Dario
- DOI
-
10.15252/embj.201798099
- URN
-
urn:nbn:de:101:1-2022091205561531184467
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Purlyte, Elena
- Dhekne, Herschel S.
- Sarhan, Adil R.
- Gomez, Rachel
- Lis, Pawel
- Wightman, Melanie
- Martinez, Terina N.
- Tonelli, Francesca
- Pfeffer, Suzanne R.
- Alessi, Dario
Ähnliche Objekte (12)
Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Parkinson’s Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32
The enzymatic core of the Parkinson’s disease-associated protein LRRK2 impairs mitochondrial biogenesis in aging yeast
Parkinson’s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes
Exosome markers of LRRK2 kinase inhibition
Leucine-rich repeat kinase 2 (Lrrk2): Functional characterization and interactome analysis of a protein kinase associated with Parkinson’s disease
Crohn’s and Parkinson’s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo
Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Parkinson’s Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32
The enzymatic core of the Parkinson’s disease-associated protein LRRK2 impairs mitochondrial biogenesis in aging yeast
Parkinson’s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes
Exosome markers of LRRK2 kinase inhibition
Leucine-rich repeat kinase 2 (Lrrk2): Functional characterization and interactome analysis of a protein kinase associated with Parkinson’s disease
Crohn’s and Parkinson’s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo
Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2
Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
Parkinson’s Disease-Associated Mutant LRRK2-Mediated Inhibition of miRNA Activity is Antagonized by TRIM32
The enzymatic core of the Parkinson’s disease-associated protein LRRK2 impairs mitochondrial biogenesis in aging yeast
Parkinson’s disease-associated LRRK2-G2019S mutant acts through regulation of SERCA activity to control ER stress in astrocytes
Exosome markers of LRRK2 kinase inhibition
Leucine-rich repeat kinase 2 (Lrrk2): Functional characterization and interactome analysis of a protein kinase associated with Parkinson’s disease
Crohn’s and Parkinson’s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo
Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization